Sinopharm Covid Vaccine May Offer Poor Protection for Elderly, Study Says

Budapest, Hungary (AP) -- A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.

A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.